Environmental and dietary risk factors in Alzheimer’s disease

References

• Herbert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol.60, 1119–1122 (2003).
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force on Alzheimer’s disease. Neurology34, 939–944 (1984).
   PubMed Web of Science ®Google Scholar
• Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci.12(10), 383–388 (1991).
   PubMed Web of Science ®Google Scholar
• Panegyras PK. The amyloid precursor protein gene: a neuropeptide gene with diverse functions in the central nervous system. Neuropeptides31, 523–535 (1997).
   PubMedGoogle Scholar
• Ponte P, Gonzalez-DeWhitt P, Schilling J et al. A new A4 amyloid mRNA contains a domain homologous to serine protease inhibitors. Nature331, 525–527 (1988).
   PubMed Web of Science ®Google Scholar
• Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL. Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s Disease. Nature331, 528–530 (1988).
   PubMed Web of Science ®Google Scholar
• Preece P, Virley DJ, Costandi M et al. Amyloid precursor protein mRNA levels in Alzheimer’s disease brain. Brain Res. Mol. Brain Res.122, 1–9 (2004).
   PubMedGoogle Scholar
• Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature357(6378), 500–503 (1992).
   PubMed Web of Science ®Google Scholar
• Goodenough S, Engert S, Behl C. Testosterone stimulates rapid secretory amyloid precursor protein release from rat hypothalamic cells via the activation of the mitogen-activated protein kinase pathway. Neurosci. Lett.296, 49–52 (2000).
   PubMed Web of Science ®Google Scholar
• Gandy S, Petanceska S. Regulation of Alzheimer β-amyloid precursor trafficking and metabolism. Biochim. Biophys. Acta.1502, 44–52 (2004).
   Google Scholar
• Seubert P, Oltersdorf T, Lee MG et al. Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide. Nature361(6049), 260–263 (1993).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature399(Suppl. 6738), A23–A31 (1999).
   PubMed Web of Science ®Google Scholar
• Wirths O, Multhaup G, Czech C et al. Intraneuronal Aβ accumulation precedes plaque formation in β-amyloid precursor protein and penicillin-1 double-transgenic mice. Neurosci. Lett.306, 116–120 (2001).
   PubMed Web of Science ®Google Scholar
• Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid β-protein beings intracellularly in cells derived from human brain. Biochemistry39(35), 10831–10839 (2000).
   PubMed Web of Science ®Google Scholar
• Rocca WA, Hofman A, Brayne C, Breteler MM, Clarke M, Copeland JR. Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann. Neurol.30(3), 381–390 (1991).
   PubMed Web of Science ®Google Scholar
• Kamboh MI. Molecular genetics of late-onset Alzheimer’s disease. Ann. Human Gen.68, 381–404 (2004).
   PubMed Web of Science ®Google Scholar
• Czech C, Tremp G, Pradier L. Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms. Prog. Neurobiol.60, 363–384 (2000).
   PubMed Web of Science ®Google Scholar
• Raiha I, Kaprio J, Koskenvuo M, Rajala T, Sourander L. Alzheimer’s disease in twins. Biomed. Pharmacother.51, 101–104 (1997).
   PubMed Web of Science ®Google Scholar
• Gatz M, Fratiglioni L, Johansson B et al. Complete ascertainment of dementia in the Swedish twin registry: the HARMONY study. Neurobiol. Aging26, 439–447 (2005).
   PubMed Web of Science ®Google Scholar
• Gee JR, Keller JN. Astrocytes: regulation of brain homeostasis via apolipoprotein E. Int. J. Biochem. Cell Biol.37(6), 1145–1150 (2005).
   PubMed Web of Science ®Google Scholar
• Wahrle SE, Jiang H, Parsadanian M et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted ApoE. J. Biol. Chem.279(39), 40987–40993 (2004).
   PubMedGoogle Scholar
• Lane RM, Farlow MR. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer’s disease. J. Lipid Res.46(5), 949–968 (2005).
   PubMed Web of Science ®Google Scholar
• Basha MR, Wei W, Bakheet SA et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and β-amyloid in the aging brain. J. Neurosci.25(4), 823–829 (2005).
   PubMed Web of Science ®Google Scholar
• Barker DJ. Fetal programming of coronary heart disease. Trends Endocrinol. Metab.13, 364–368 (2002).
   PubMed Web of Science ®Google Scholar
• Bush AI. The metallobiology of Alzheimer’s disease. Trends Neurosci.26(4), 207–214 (2003).
   PubMed Web of Science ®Google Scholar
• Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer’s disease: possible relation to oxidative stress. J. Neurol. Sci.143, 137–142 (1996).
   PubMed Web of Science ®Google Scholar
• Groves JT. Bioinorganic chemistry special feature: the bioinorganic chemistry of iron in oxygenases and supramolecular assemblies. Proc. Natl Acad. Sci. USA100, 3569–3574 (2003).
   PubMedGoogle Scholar
• Fraunfelder H, McMahon BH, Austen RH, Chu K, Groves JT. The role of structure, energy landscape, dynamics and allostery in the enzymatic function of myoglobin. Proc. Natl Acad. Sci. USA98(5), 2370–2374 (2001).
   PubMedGoogle Scholar
• Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol.14(6), 611–650 (2001).
   PubMed Web of Science ®Google Scholar
• Atamna H, Boyle K. Amyloid-β peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer’s disease. Proc. Natl Acad. Sci. USA103(9), 3381–3386 (2006).
   PubMed Web of Science ®Google Scholar
• Opazo C, Huang X, Cherny RA et al. Metalloenzyme-like activity of Alzheimer’s disease β-amyloid: Cu dependent catalytic conversion of dopamine, cholesterol and biological reducing agents to neurotoxic H2O2. J. Biol. Chem.2777(43), 40302–40308 (2002).
   Google Scholar
• Cole TB, Wenzel HJ, Kafer KE, Schwartzkroin PA, Palmiter RD. Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc. Natl Acad. Sci. USA96(4), 1716–1721 (1999).
   PubMed Web of Science ®Google Scholar
• Yu WH, Lukiw WJ, Bergeron C, Niznik HB, Fraser PE. Metallothionein III is reduced in Alzheimer’s disease. Brain Res.894(1), 37–45 (2001).
   PubMedGoogle Scholar
• Religa D, Strozyk D, Cherny RA et al. Elevated cortical zinc in Alzheimer’s disease. Neurology67, 69–75 (2006).
   PubMed Web of Science ®Google Scholar
• Perry G, Taddeo MA, Peterson RB et al. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer’s disease. Biometals16, 77–81 (2003).
   PubMed Web of Science ®Google Scholar
• Maynard CJ, Bush AI, Masters CL, Cappai R, Li Q-X. Metals and amyloid-β in Alzheimer’s disease. Int. J. Exp. Path.86, 147–159 (2005).
   PubMed Web of Science ®Google Scholar
• Atwood C, Scarpa RC, Huang T et al. Characterization of copper interactions with Alzheimer amyloid β peptides: identification of an attomolar-affinity copper binding site on amyloid β1–42. J. Neurochem.75, 1219–1233 (2000).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Schreurs BG. Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA100(19), 11065–11069 (2003).
   PubMed Web of Science ®Google Scholar
• Barceloux DG. Copper. Clin. Toxicol.37(2), 217–230 (1999).
   Web of Science ®Google Scholar
• Abe T, Tohgi H, Isobe C, Murata T, Sato C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer’s disease. J. Neurosci. Res.70(3), 447–450 (2002).
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Alterations of 3-nitrotyrosine concentration in the cerebrospinal fluid during aging and in patients with Alzheimer’s disease. Neurosci. Lett.269(1), 52–54 (1999).
   PubMed Web of Science ®Google Scholar
• Montine TJ, Markesbery WR, Morrow JD, Roberts LJ. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer’s disease. Ann. Neurol.44(3), 410–413 (1998).
   PubMed Web of Science ®Google Scholar
• McLachlan DR, Kruck TP, Lukiw WJ, Krishnan SS. Would decreased aluminum ingestion reduce the incidence of Alzheimer’s disease. Can. Med. Assoc. J.145(7), 793–804 (1991).
   PubMed Web of Science ®Google Scholar
• Beal MF, Mazurek MF, Ellison DW, Kowall NW, Solomon PR, Pendlebury WW. Neurochemical characteristics of aluminum-induced neurofibrillary degeneration in rabbits. Neuroscience29(2), 339–346 (1989).
   PubMed Web of Science ®Google Scholar
• Nehru B, Anand P. Oxidative damage following chronic aluminum exposure in adult and pup rat brains. J. Trace Elem. Med. Biol.19, 203–208 (2005).
   PubMed Web of Science ®Google Scholar
• Exely C. A molecular mechanism of aluminum-induced Alzheimer’s disease? J. Inorg. Biochem.76, 133–140 (1999).
   PubMedGoogle Scholar
• Klatzo I, Wisniewski H, Streicher E. Experimental production of neurofibrillary degeneration: light microscope observations. J. Neuropathol. Exp. Neurol.24, 187–199 (1965).
   PubMed Web of Science ®Google Scholar
• Shin R, Lee VM, Trojanowski JQ. Aluminum modifies the properties of Alzheimer’s disease PHFτ proteins in vivo and in vitro.J. Neurosci.14(11), 7221–7233 (1994).
   PubMedGoogle Scholar
• Muma NA, Singer SM. Aluminum-induced neuropathology: transient changes in microtubule-associated proteins. Neurotoxicol. Teratol.18(6), 679–690 (1996).
   PubMed Web of Science ®Google Scholar
• Tokutake S, Nagase H, Morisake S, Oyanagi S. Aluminum detected in senile plaques and neurofibrillary tangles is contained in lipofuscin granules with silicon probably as aluminosilicate. Neurosci. Lett.185, 99–102 (1995).
   PubMed Web of Science ®Google Scholar
• Lovell MA, Ehmann WD, Markesbery WR. Laser microprobe analysis of brain aluminum in Alzheimer’s disease. Ann. Neurol.33(1), 36–42 (1993).
   PubMedGoogle Scholar
• Amaducci LA, Fratiglioni L, Rocca WA et al. Risk factors for clinically diagnosed Alzheimer’s disease: a case-control study of an Italian population. Neurology36, 922–931 (1986).
   PubMed Web of Science ®Google Scholar
• Wettstein A, Aeppli j, Gautschi K, Peters M. Failure to find a relationship between amnestic skills of octogenarians and aluminum in drinking water. Int. Arch. Occup. Environ. Health63, 97–103 (1991).
   PubMed Web of Science ®Google Scholar
• Munoz DG, Feldman H. Causes of Alzheimer’s disease. Can. Med. Assoc. J.162, 65–72 (2000).
   PubMedGoogle Scholar
• Krigman MR, Bouldin TW, Mushak P. Lead. Experimental and Clinical Neurotoxicology. Spencer PS, Schaumburg HH (Eds). Oxford University Press, NY, USA 490–507 (1980).
   Google Scholar
• Barry PSI, Mossman DB. Lead concentrations in human tissues. Br. J. Ind. Med.27, 339–351 (1970).
   PubMedGoogle Scholar
• Meyer PA, Pivetz T, Dignam TA, Homa DM, Schoonover J, Brody D. Surveillance for elevated blood lead levels among children – United States, 1997–2001. Morb. Mortal. Wkly Rep.52(SS10), 1–21 (2003).
   PubMedGoogle Scholar
• Canfield RL, Henderson CR, Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. Intellectual impairment in children with blood lead concentrations below 10 µg per deciliter. N. Engl. J. Med.348(16), 1517–1526 (2003).
   PubMed Web of Science ®Google Scholar
• Needleman HL, Gunnoe C, Leviton A et al. Deficits in psychologic and classroom performance of children with elevated dentine lead levels. N. Engl. J. Med.300(13), 689–695 (1979).
   PubMed Web of Science ®Google Scholar
• Schwartz BS, Stewart WF, Bolla KI et al. Past adult lead exposure is associated with longitudinal decline in cognitive function. Neurology55, 1144–1150 (2000).
   PubMed Web of Science ®Google Scholar
• Stewart WF, Schwartz BS, Davatzikos C et al. Past adult lead exposure is linked to neurodegeneration measured by brain MRI. Neurology66, 1476–1484 (2006).
   PubMed Web of Science ®Google Scholar
• Lindahl LS, Bird L, Legare ME, Mikeska G, Bratton GR, Tiffany-Castiglioni E. Differential ability of astroglia and neuronal cells to accumulate lead: dependence on cell type and on degree of differentiation. Toxiocol. Sci.50(2), 236–243 (1999).
   PubMed Web of Science ®Google Scholar
• Qian Y, Harris ED, Zheng Y, Tiffany-Castiglioni E. Lead targets GRP78, a molecular chaperone in C6 rat glioma cells. Toxicol. Appl. Pharmacol.163(3), 260–266 (2000).
   PubMed Web of Science ®Google Scholar
• Reyes PF, Gonzalez CF, Zalewska MK, Besarab A. Intracranial calcification in adults with chronic lead exposure. Am. J. Roentgenol.146(2), 267–270 (1986).
   PubMedGoogle Scholar
• Haraguchi T, Ishizu H, Takehisa Y et al. Lead content of brain tissue in diffuse neurofibrillary tangles with calcification (DNTC): the possibility of lead neurotoxicity. Neuroreport12(18), 3887–3890 (2001).
   PubMed Web of Science ®Google Scholar
• Niklowitz WJ, Mandybur TI. Neurofibrillary changes following childhood lead encephalopathy. J. Neuropathol. Exp. Neurol.34(5), 445–455 (1975).
   PubMedGoogle Scholar
• Basha MR, Wei W, Brydie M, Razmiafshari M, Zawia NH. Lead-induced developmental perturbations in hippocampal Sp1 DNA-binding are prevented by zinc supplementation: in vivo evidence for Pb and Zn competition. Int. J. Dev. Neurosci.21, 1–12 (2003).
   PubMed Web of Science ®Google Scholar
• Basha MR, Manjari M, Siddiqi HK et al. Lead (Pb) exposure and its effect on APP proteolysis and Aβ aggregation. FASEB J.19, 2083–2084 (2005).
   PubMedGoogle Scholar
• Klassen CD. Nonmetallic environmental toxicants: air pollutants, solvents and vapors, and pesticides. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics (9th Edition). Hardman JG, Limbird LE (Eds). McGraw-Hill Companies Inc., OH, USA 1673–1696 (1996).
   Google Scholar
• US EPA Air Quality Criteria for Particulate Matter. 600/P-99/002aF-bF. Environmental Protection Agency (2004).
   Google Scholar
• Calderon-Garcinduenas L, Maronpot RR, Torres-Jardon R et al. DNA damage in nasal and brain tissues of canines exposed to air pollutants is associated with evidence of chronic brain inflammation and neurodegeneration. Toxicol. Pathol.31, 524–538 (2003).
   PubMedGoogle Scholar
• Calderon-Garcinduenas L, Reed W, Maronpot RR et al. Brain inflammation and Alzheimer’s-like pathology in individuals exposed to severe air pollution. Toxicol. Pathol.32, 650–658 (2004).
   PubMedGoogle Scholar
• Koenig JQ, Pierson WE. Air pollutants and the respiratory system: toxicity and pharmacologic interventions. J. Toxicol. Clin. Toxicol.29(3), 401–411 (1991).
   PubMed Web of Science ®Google Scholar
• Neas LM, Dockery DW, Burge H, Koutraki P, Speizer FE. Fungus spores, air pollutants, and other determinants of peak expiratory flow rate in children. Am. J. Epidemiol.143(8), 797–807 (1996).
   PubMed Web of Science ®Google Scholar
• Rahman Q, Norwood J, Hatch G. Evidence that exposure of particulate air pollutants to human and rat alveolar macrophages leads to differential oxidative response. Biochem. Biophys. Res. Commun.240, 669–672 (1997).
   PubMed Web of Science ®Google Scholar
• Ross MA, Persky VW, Schef PA et al. Effect of ozone and aeroallergens on the respiratory health of Asthmatics. Arch. Environ. Health57(6), 568–578 (2002).
   PubMed Web of Science ®Google Scholar
• Brown JS, Zeman KL, Bennett WD. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am. J. Respir. Care Med.166, 1240–1247 (2002).
   PubMed Web of Science ®Google Scholar
• Mills NL, Amin N, Robinson SD et al. Do inhaled carbon nanoparticles translocate directly into the circulation in humans? Am. J. Respir. Care Med.173, 426–431 (2006).
   PubMed Web of Science ®Google Scholar
• Peters A, Veronesi B, Calderon-Garcinduenas L et al. Translocation and potential neurological effects of fine and ultrafine particles a critical update. Part. Fibre Toxicol.3, 13 (2006).
   PubMed Web of Science ®Google Scholar
• Risom L, Moller P, Loft S. Oxidative stress-induced DNA damage by particulate air pollution. Mut. Res.592, 119–137 (2005).
   PubMed Web of Science ®Google Scholar
• Oberdorster G, Sharp Z, Atudorei V et al. Translocation of inhaled ultrafine particles to the brain. Inhal. Toxicol.16, 437–445 (2004).
   PubMed Web of Science ®Google Scholar
• Ubogu E, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol. Sci.27(1), 48–55 (2006).
   PubMed Web of Science ®Google Scholar
• Corasantini MT, Delfilippo R, Rodino P, Nappi G, Nistico G. Evidence that paraquat is able to cross the blood–brain barrier to a different extent in rats of various age. Func. Neurol.6(4), 385–391 (1991).
   PubMedGoogle Scholar
• Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson’s disease and brain levels of organochlorine pesticides. Ann. Neurol.36(1), 100–103 (1994).
   PubMed Web of Science ®Google Scholar
• Gauthier E, Fortier I, Courchesne F, Pepin P, Mortimer J, Gauvreau D. Environmental pesticide exposure as a risk factor for Alzheimer’s disease: a case-control study. Environ. Res.86, 37–45 (2001).
   PubMed Web of Science ®Google Scholar
• Schulte PA, Burnett CA, Boeniger MF, Johnson J. Neurodegenerative diseases: occupational and occurrence and potential risk factors, 1982 through 1991. Am. J. Pub. Health86(9), 1281–1288 (1996).
   PubMed Web of Science ®Google Scholar
• Baldi I, Lebailly P, Mohammed-Brahim B, Letenneur L, Dartiques JF, Brochard P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am. J. Epidemiol.157(5), 409–414 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor P. Anticholinesterase agents. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics (9th Edition). Hardman JG, Limbird LE (Eds). McGraw-Hill Companies Inc., OH, USA 161–176 (1996).
   Google Scholar
• Boyd CA, Weiler MH, Porter WP. Behavioral and neurochemical changes associated with chronic exposure to low-level concentration of pesticide mixtures. J. Toxicol. Environ. Health30, 209–221 (1990).
   PubMed Web of Science ®Google Scholar
• Karczmar A. Invited review: anticholinesterases: dramatic aspects of their use and misuse. Neurochem. Int.32, 401–411 (1998).
   PubMed Web of Science ®Google Scholar
• Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science21, 408–417 (1982).
   Google Scholar
• Peters BH, Levin HS. Effects of physostigmine and lecithin on memory in Alzheimer’s disease. Ann. Neurol.6(3), 219–221 (1979).
   PubMed Web of Science ®Google Scholar
• Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Kopell BS. Physostigmine: improvement of long-term memory processes in normal humans. Science201, 272–274 (1978).
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology57, 613–620 (2001).
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P. Functional, cognitive and behavioral effects of donepezil in patients with Alzheimer’s disease. Curr. Med. Res. Opin.18(6), 347–354 (2002).
   PubMed Web of Science ®Google Scholar
• Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA271(13), 985–991 (1994).
   PubMed Web of Science ®Google Scholar
• Lahiri DK, Rogers JT, Greig NH, Sambamurti K. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer’s agents. Curr. Pharm. Des.10, 3111–3119 (2004).
   PubMed Web of Science ®Google Scholar
• Wang J, Ho L, Qin W et al. Caloric restriction attenuates β-amyloid neuropathology in a mouse model of Alzheimer’s disease. FASEB J.19(6), 659–661 (2005).
   PubMed Web of Science ®Google Scholar
• Luchinger JA, Tang MX, Miller J, Shea S, Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch. Neurol.59, 1258–1263 (2002).
   PubMedGoogle Scholar
• Ott A, Stolk RP, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam study. Diabetologia39, 1392–1397 (1996).
   PubMed Web of Science ®Google Scholar
• Zhao L, Teter B, Morihara T et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention. J. Neurosci.24(49), 11120–11126 (2004).
   PubMed Web of Science ®Google Scholar
• Farris W, Mansourian S, Chang Y et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo.Proc. Natl Acad. Sci. USA100(7), 4162–4167 (2003).
   PubMed Web of Science ®Google Scholar
• Qin W, Yang T, Ho L et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem.281(31), 21745–21754 (2006).
   PubMed Web of Science ®Google Scholar
• Anekonda TS. Resveratrol – a boon for treating Alzheimer’s disease. Brain Res. Brain Res. Rev.52, 316–326 (2006).
   PubMed Web of Science ®Google Scholar
• Seshadri S, Beiser A, Selhub J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N. Engl. J. Med.346, 476–483 (2002).
   PubMed Web of Science ®Google Scholar
• Miller JW, Nadeau MR, Smith D, Selhub J. Vitamin B-6 deficiency vs folate deficiency: comparison of responses to methionine loading in rats. Am. J. Clin. Nutr.59, 1033–1039 (1994).
   PubMed Web of Science ®Google Scholar
• Miller AL, Kelly GS. Methionine and homocysteine metabolism and the nutritional prevention of certain birth defects and complications of pregnancy. Altern. Med. Rev.1(4), 220–235 (1996).
   Google Scholar
• Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin signaling, and glutathione has a protective effect. J. Molec. Endocrinol.27, 85–91 (2001).
   PubMed Web of Science ®Google Scholar
• Guidi I, Galimberti D, Lonati S et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer’s disease. Neurobiol. Aging27, 262–269 (2006).
   PubMedGoogle Scholar
• Morris MC, Evans DA, Schneider JA, Tangney CC, Bienias JL, Aggarwal NT. Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer’s disease. J. Alzheimers Dis.9(4), 435–443 (2006).
   PubMed Web of Science ®Google Scholar
• Annerbo S, Wahlund L, Lökk J. The relation between homocysteine levels and development of Alzheimer’s disease in mild cognitive impairment patients. Dement. Geriatr. Cogn. Dis.20(4), 209–214 (2005).
   PubMedGoogle Scholar
• Kado DM, Karlamangla AS, Huang M et al. Homocysteine versus the vitamins folate, B6 and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am. J. Med.118, 161–167 (2005).
   PubMed Web of Science ®Google Scholar
• Ravaglia G, Forti P, Maioli F et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am. J. Clin. Nutr.82, 636–643 (2005).
   PubMed Web of Science ®Google Scholar
• Ariogula S, Cankurtarana M, Dagli N, Khalila M, Yavuz B. Vitamin B12, folate, homocysteine and dementia: are they really related? Arch. Gerontol. Geriatr.40, 139–146 (2005).
   PubMedGoogle Scholar
• Wang B, Jin F, Kan R et al. Association of MTHFR gene polymorphism C677T with susceptibility to late-onset Alzheimer’s disease. J. Mol. Neurosci.27(1), 23–27 (2005).
   PubMed Web of Science ®Google Scholar
• Kamath AF, Chauhan AK, Kisucka J et al. Elevated levels of homocysteine compromise blood–brain barrier integrity in mice. Blood107(2), 591–593 (2006).
   PubMed Web of Science ®Google Scholar
• Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S et al. Hyperhomocysteinemic Alzheimer’s mouse model of amyloidosis shows increased brain amyloid β peptide levels. Neurobiol. Dis.22, 651–656 (2006).
   PubMedGoogle Scholar
• Santiard-Baron D, Aupetit J, Janel N. Plasma homocysteine levels are not increased in murine models of Alzheimer’s disease. Neurosci. Res.53, 447–449 (2005).
   PubMedGoogle Scholar
• Lehmann M, Regland B, Blennow K, Gottfries CG. Vitamin B12-B6-folate treatment improves blood–brain barrier function in patients with hyperhomocysteinemia and mild cognitive impairment. Dement. Geriatr. Cogn. Disord.16, 145–150 (2003).
   PubMed Web of Science ®Google Scholar
• Irizarry MC, Gurol ME, Raju S et al. Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease. Neurology65(9), 1402–1408 (2005).
   PubMed Web of Science ®Google Scholar
• Jarvik GP, Wijsman EM, Kukull WA, Schellenber GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer’s disease: a case-control study. Neurology45(6), 1092–1096 (2005).
   Google Scholar
• Hofman A, Ott A, Breteler MM et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam study. Lancet349(9046), 151–154 (1997).
   PubMed Web of Science ®Google Scholar
• Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR. Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology62(10), 1869–1871 (2004).
   PubMed Web of Science ®Google Scholar
• Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet356(9242), 1627–1631 (2000).
   PubMed Web of Science ®Google Scholar
• Rockwood K, Kirkland S, Hogan DB et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol.59(2), 223–227 (2002).
   PubMed Web of Science ®Google Scholar
• Tokuda T, Tamaoka A, Matsuno S et al. Plasma levels of amyloid β proteins did not differ between subjects taking statins and those not taking statins. Ann. Neurol.49, 546–547 (2001).
   PubMedGoogle Scholar
• Ishii K, Tokuda T, Matsushima T et al. Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans. Neurosci. Lett.350, 161–164 (2003).
   PubMedGoogle Scholar
• Beffert U, Danik M, Krzywkowski P, Ramassamy C, Berrada F, Poirier J. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer’s disease. Brain Res. Rev.27, 119–142 (1998).
   PubMedGoogle Scholar
• Ghribi O, Golovko MY, Larsen B, Schrag M, Murphy EJ. Deposition of iron and β-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J. Neurochem.99, 438–449 (2006).
   PubMed Web of Science ®Google Scholar
• Borroni B, Grassi M, Costanzi C, Archetti S, Caimi L, Padovani A. APOE genotype and cholesterol levels in lewy body dementia and Alzheimer disease: investigating genotype–phenotype effect on disease risk. Am. J. Geriatr. Psychiatry14, 1022–1031 (2006).
   PubMedGoogle Scholar
• Puglielli L, Friedlich AL, Setchell KDR et al. Alzheimer disease β-amyloid activity mimics cholesterol oxidase. J. Clin. Invest.115, 2556–2563 (2005).
   PubMed Web of Science ®Google Scholar
• Hutter-Paier B, Huttunen H, Puglielli L et al. The ACAT inhibitor CP-113, 818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron44(2), 227–238 (2004).
   PubMed Web of Science ®Google Scholar
• Nelson TJ, Alkon DL. Oxidation of cholesterol by amyloid precursor protein and β-amyloid peptide. J. Biol. Chem.280(8), 7377–7387 (2005).
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol.24, 806–815 (2004).
   PubMed Web of Science ®Google Scholar
• Papassotiropoulos A, Streffer JR, Tsolaki M et al. Increased brain β-amyloid load, phosphorylated τ, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol.60, 29–35 (2003).
   PubMedGoogle Scholar
• Borroni B, Archetti S, Agosti C et al. Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer disease: from risk factors to disease modulators. Neurobiol. Aging25(6), 747–751 (2004).
   PubMed Web of Science ®Google Scholar
• Li Y, Chu LW, Chen YQ, St. George-Hyslop P, Song YQ. Intron 2 (T/C) CYP46 polymorphism is associated with Alzheimer’s disease in Chinese patients. Dement. Geriatr. Cogn. Disord.22, 399–404 (2006).
   PubMedGoogle Scholar
• Heverin M, Bodganovic N, Lütjohann D et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J. Lipid Res.45, 186–193 (2004).
   PubMed Web of Science ®Google Scholar
• Wirths O, Thelen K, Breyhan H et al. Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer’s disease. Exp. Gerontol.41(2), 220–224 (2006).
   PubMedGoogle Scholar
• Kuusisto J, Koivisto K, Mykkanen L et al. Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein E4 phenotype: cross sectional population based study. Br. Med. J.315(7115), 1045–1049 (1997).
   PubMed Web of Science ®Google Scholar
• Solfrizzi V, Panza F, D’Introno A et al. Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry72(6), 732–736 (2002).
   PubMedGoogle Scholar
• Panza F, D’Introno A, Colacicco AM et al. Lipid metabolism in cognitive decline and dementia. Brain Res. Rev.51(2), 275–292 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart R, White LR, Xue QL, Launer LJ. Twenty-six year change in total cholesterol levels and incident dementia: the Honolulu–Asia Aging Study. Arch Neurol.64(1), 103–107 (2007).
   PubMed Web of Science ®Google Scholar
• Lambert JC, Chartier-Harlin MC, Cottel D et al. Is the LDL receptor-related protein involved in Alzheimer’s disease? Neurogenetics2(2), 109–113 (1999).
   PubMedGoogle Scholar
• Tully AM, Roche HM, Doyle R et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer’s disease: a case–control study. Br. J. Nutr.89(4), 483–490 (2003).
   PubMed Web of Science ®Google Scholar
• Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol.63(10), 1402–1408 (2006).
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Bongard V, Beiser AS et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch. Neurol.63(11), 1545–1550 (2006).
   PubMed Web of Science ®Google Scholar
• Calon F, Lim GP, Morihara T et al. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer’s disease. Eur. J. Neurosci.22(3), 617–626 (2005).
   PubMed Web of Science ®Google Scholar
• Florent S, Malaplate-Armand C, Youssef I et al. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-β oligomers. J. Neurochem.96(2), 385–395 (2006).
   PubMed Web of Science ®Google Scholar
• Oksman M, Iivonen H, Hogyes E et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on β-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis.23, 563–572 (2006).
   PubMed Web of Science ®Google Scholar
• Lukiw WJ, Cui J-G, Marcheselli VL et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest.115, 2774–2783 (2005).
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Gnjec A, Poon HF et al. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer’s disease: an initial assessment. J. Alzheimers Dis.10(4), 391–397 (2006).
   PubMed Web of Science ®Google Scholar
• Sultana R, Newman SF, Abdul HM et al. Protective effect of D609 against amyloid-β1–42-induced oxidative modification of neuronal proteins: redox proteomics study. J. Neurosci. Res.84(2), 409–417 (2006).
   PubMedGoogle Scholar
• Sultana R, Boyd-Kimball D, Poon HF et al. Redox proteomics identification of oxidized proteins in Alzheimer’s disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging27(11), 1564–1576 (2006).
   PubMed Web of Science ®Google Scholar
• Wang J, Ho L, Zhao Z et al. Moderate consumption of Cabernet Sauvignon attenuates Aβ neuropathology in a mouse model of Alzheimer’s disease. FASEB J.20(13), 2313–2320 (2006).
   PubMed Web of Science ®Google Scholar
• Yang F, Lim GP, Begum AN et al. Curcumin inhibits formation of amyloid oligomers and fibrils, binds plaques, and reduces amyloid in vivo.J. Biol. Chem.280(7), 5892–5901 (2005).
   PubMed Web of Science ®Google Scholar
• Savaskan E, Olivieri G, Meier F, Seifritz E, Wirz-Justice A, Muller-Spahn F. Red wine ingredient resveratrol protects from β-amyloid neurotoxicity. Gerontology49(6), 380–383 (2003).
   PubMed Web of Science ®Google Scholar
• Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer’s disease amyloid-β peptides. J. Biol. Chem.280(45), 37377–37382 (2005).
   PubMed Web of Science ®Google Scholar
• de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res.49(5), 405–430 (2005).
   PubMed Web of Science ®Google Scholar
• Labinskyy N, Csiszar A, Veress G et al. Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. Curr. Med. Chem.13(9), 989–996 (2006).
   PubMed Web of Science ®Google Scholar
• Kim YA, Lim SY, Rhee SH et al. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β-amyloid-treated C6 glioma cells. Int. J. Mol. Med.17(6), 1069–1075 (2006).
   PubMed Web of Science ®Google Scholar
• Staehelin HB. Micronutrients and Alzheimer’s disease. Proc. Nutr. Soc.64, 565–570 (2005).
   PubMed Web of Science ®Google Scholar
• Morris MC, Evans DA, Bienias JL et al. Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline. J. Neurol. Neurosurg. Psychiatry75, 1093–1099 (2004).
   PubMed Web of Science ®Google Scholar
• Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch. Neurol.63(12), 1709–1717 (2006).
   PubMed Web of Science ®Google Scholar